Table 1 Baseline characteristics of the study population, stratified by disease behavior

Demographic data

n = 122

n = 54

n = 68

Age (years)

32.5 ± 12.04

33.85 ± 12.70

30.79 ± 11.41

Sex

 Male

95

39

56

 Female

27

15

12

Current smoker

 Yes

15

10

5

 No

107

44

63

Location^a

 L1

49

26

23

 L2

27

11

16

 L3

46

17

29

Perianal disease

 Yes

32

13

19

 No

90

41

49

Duration of disease (years)

2.19 ± 2.93

2.33 ± 2.90

2.08 ± 2.97

C-reactive protein (mg/L)^b

43.03 ± 41.41 (n = 107)

47.02 ± 48.08 (n = 44)

40.25 ± 36.19 (n = 63)

Serum albumin (g/L)^b

35.13 ± 6.67 (n = 120)

34.66 ± 6.78 (n = 54)

35.52 ± 6.57 (n = 66)

Erythrocyte sedimentation rate (mm/h)^b

26.59 ± 22.75 (n = 111)

27.67 ± 23.82 (n = 46)

25.82 ± 22.12 (n = 65)

BMI (kg/m²)

18.49 ± 2.80

17.88 ± 2.66

19.19 ± 2.82

Sacorpenia

 Yes

84

39

45

 No

38

15

23

Baseline medications

Diagnostic anti-tuberculosis therapy

30

8

22

Nutritional supplement

106

51

55

Anti-TNF

20

11

9

Corticosteroids

30

9

21

Immunomodulator

16

5

11

Mesalazine

58

20

38

Follow-up outcomes

Adverse outcome

n = 49

n = 31

n = 18

Surgery

32

20

12

Start of anti-TNF therapy

4

2

2

Escalation of biologic therapy

13

9

4